DIA Recap: Monday, June 15
Jun 15, 2020

During this critical moment in global healthcare, the show must go on for the largest and longest-running life sciences industry event— just virtually! 

IQVIA is pleased to be a leading sponsor of 2020 DIA Global Annual Meeting this week, where our experts will be leading a variety of discussions to help the industry tackle complex challenges and brainstorm ways to continue bringing much-needed therapies to patients regardless of potential roadblocks. 

During this first full day of programming, several IQVIA leaders articulated actionable insights to help clinical trial sponsors and the broader industry continue studying disease and driving innovation during the COVID-19 crisis and beyond.

Here’s a brief recap of their Innovation Theater presentations, which are available to DIA conference registrants to view on demand for the next 60 days.

  • During “COVID-19 Disruption Provides a Pivotal Opportunity to Accelerate Patient Engagement Innovation,” Erica Prowisor, global head, Recruitment and Retention for IQVIA Research and Development Solutions, discussed IQVIA’s strategies for maintaining trial continuity in a complicated new era of clinical research. Recognizing this time in history as a unique opportunity to accelerate patient-centric innovation, Prowisor discussed how IQVIA is laser-focused on mobilizing its wide breadth of data, technology, analytics and expertise to unite all stakeholders (e.g., sponsors, site teams, and patients) and rethink how to deliver more agile recruitment strategies. Through IQVIA’s Direct-to-Patient Recruitment solution, the team is using an innovative, holistic digital approach, to drive productivity to safely identify, recruit and retain the right patients for each trial while reducing the burden on site and study teams.
  • More than ever, patients want know about their treatment and should be treated as valued partners in clinical development. In the “Digital Patient Experience/Virtual Trials” presentation, IQVIA’s MaryAnne Rizk, senior vice president, Research and Development Solutions Digital Strategy, and Jean Paty, vice president, Patient Centered Sciences, spoke about the importance of creating a patient-centric experience from molecule to market for all stakeholders. Today, IQVIA offers a new SaaS-based cloud platform called Orchestrated Clinical Trials to produce an uninterrupted flow of data-driven evidence to quickly close the gap between data collection and decision-making and allow study teams and sponsors to better understand and respond to patient needs. 
On Sunday, as part of the preconference course “Real World Evidence: The Evolving Landscape of Regulators, Data, and Integrated Use,” IQVIA Real World Solutions Chief Scientific Officer Nancy Dreyer and Matthew Reynolds, vice president, Real World Evidence, shared how real-world evidence is used to generate actionable insights in major markets globally. While evidence generation primarily focuses on regulatory use, Nancy and Matthew, alongside Amgen leaders Brian Bradbury and Gillis Carrigan, explained key epidemiological design principles critical to interpreting the quality and validity of real-world evidence studies as identified by the U.S. Food and Drug Administration in late 2019. The course also noted the current status of the FDA’s guidance on when real world studies will sufficiently meet regulatory evidence requirements. 


It’s been a great start to DIA 2020! As informative and exciting discussions continue this week, we will continue providing daily roundups of the sessions highlighting IQVIA and industry experts’ discussions on ways to improve health globally. 


Already attending DIA? We invite you to visit the IQVIA virtual booth or contact us here to schedule a meeting with one of our experts and learn more about the ways IQVIA is driving healthcare forward.  
You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.